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Background: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may
report only patients who underwent resection and so survival will be skewed. The aim of this study was
to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment
in resectable or borderline resectable pancreatic cancer.
Methods: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median
overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer
treated with or without neoadjuvant treatment. Secondary outcomes included overall and R0 resection
rate, pathological lymph node rate, reasons for unresectability and toxicity of neoadjuvant treatment.
Results: In total, 38 studies were included with 3484 patients, of whom 1738 (49⋅9 per cent) had
neoadjuvant treatment. The weighted median overall survival by intention to treat was 18⋅8months for
neoadjuvant treatment and 14⋅8months for upfront surgery; the difference was larger among patients
whose tumours were resected (26⋅1 versus 15⋅0months respectively). The overall resection rate was lower
with neoadjuvant treatment than with upfront surgery (66⋅0 versus 81⋅3 per cent; P<0⋅001), but the R0
rate was higher (86⋅8 (95 per cent c.i. 84⋅6 to 88⋅7) versus 66⋅9 (64⋅2 to 69⋅6) per cent; P< 0⋅001). Reported
by intention to treat, the R0 rates were 58⋅0 and 54⋅9 per cent respectively (P= 0⋅088). The pathological
lymph node rate was 43⋅8 per cent after neoadjuvant therapy and 64⋅8 per cent in the upfront surgery
group (P<0⋅001). Toxicity of at least grade III was reported in up to 64 per cent of the patients.
Conclusion: Neoadjuvant treatment appears to improve overall survival by intention to treat, despite
lower overall resection rates for resectable or borderline resectable pancreatic cancer.
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Introduction
Pancreatic cancer is recognized as having an overall poor
prognosis and low resection rate. Long-term survival
remains limited even after tumour resection. Surgical
resection with adjuvant chemotherapy is the current stan-
dard of care1. Recent trials1,2 have reported improved
median overall survival to 24⋅5–28months with adjuvant
treatment. However, these trials did not report how many
eligible patients were fit enough to be randomized to
receive adjuvant chemotherapy. Currently, the strongest
predictors of survival include surgery with curative intent,
early-stage disease and complete (R0) resection3,4. None
of these predictors are influenced by adjuvant treatment.
In patients with resectable pancreatic cancer, a recent
study5 of Surveillance, Epidemiology, and End Results
(SEER) data from nearly 4000 patients suggested a
survival benefit with neoadjuvant radiotherapy with or
without chemotherapy over upfront surgery with or with-
out adjuvant treatment. However, RCTs of neoadjuvant
treatment compared with upfront surgery are lacking.
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Non-randomized studies evaluating neoadjuvant treat-
ment of patients with either borderline resectable or
upfront resectable pancreatic cancer often suffer from
selection bias because they report survival data only for
patients who eventually underwent pancreatic resection.
Patients with disease progression or severe toxicity who
did not undergo resection are often excluded. Moreover,
patients found to have metastatic or unresectable disease
at exploratory surgery are also excluded5,6.
The aim of this study was to perform a systematic review
of studies comparing median overall survival of patients
who underwent upfront surgery versus those who under-
went neoadjuvant treatment in intention-to-treat analyses.
Methods
The systematic review was performed according to the
PRISMA guidelines7. The review was registered at PROS-
PERO (registration number: CRD42016049374).
Search strategy
The literature was reviewed systematically by searching in
MEDLINE, Embase and the Cochrane Library for studies
published between 1 January 2000 and 6 December 2016.
The search strategy included the following domains of
Medical Subject Heading (MeSH) terms: ‘pancreatic neo-
plasm’, ‘survival’, ‘mortality’ and ‘survival analysis’; these
were combined with ‘AND’ or ‘OR’. No language restric-
tions were used. For theMEDLINE and Embase searches,
aMcMaster specific prognosis filter was applied, completed
with the authors’ own terminology to cover the survival
concept of the search strategy. A full description of the
search is available in Appendix S1 (supporting information).
Eligibility
Studies including patients with resectable or borderline
resectable pancreatic cancer, either treated by upfront
surgery or with neoadjuvant treatment, and reporting
median overall survival by intention to treat (based on
the initial treatment assignment and not on the treatment
eventually received) were included. No selection was made
based on adjuvant treatment. Excluded were review arti-
cles, notes, letters, case reports (5 or fewer patients), animal
studies, studies that did not report median overall survival
by intention to treat, and studies that reported on only
specific groups of patients (for example, those with renal
impairment, older than 70 years, or with poor performance
status). Studies that did not report median overall survival
separately for resectable and borderline resectable pancre-
atic tumours were also excluded.
Study selection
Two authors screened the titles and abstracts independently
for eligibility. After the first two rounds of screening,
full-text screening was carried out. Disagreements were
resolved by discussion and consensus achieved. Primary
and secondary outcomes were extracted from the full text.
If studies had an overlapping cohort, the most recent study
was included.
Methodological quality
All studies were assessed for risk of bias using a stan-
dard list of 11 potential risks of bias, based on the Oxford
Centre for Evidence-Based Medicine (CEBM) Critical
Appraisal Skills Programme checklists for randomized tri-
als and observational cohort studies, and the Cochrane
Collaboration’s tool for assessing risk of bias8–11. All stud-
ies were graded according to the Oxford CEBM levels of
evidence12.
Outcome measures
The primary outcome, median overall survival, was
extracted from the included articles. Data on numbers of
patients with (borderline) resectable pancreatic cancer,
resectability criteria (for example, those of the National
Comprehensive Cancer Network (NCCN) and American
Hepato-Pancreato-Biliary Association (AHPBA)), and
types of neoadjuvant treatment and adjuvant treatment
were obtained. Secondary outcomes were: resection rate,
completeness of resection (R0 resection rate, only for
patients undergoing resection), pathological lymph node
rate, reasons for unresectability, and toxicity of at least
grade III after neoadjuvant treatment.
Statistical analyses
The weighted median overall survival was calculated for
the studies reporting this information for groups with and
without neoadjuvant treatment. The weighted estimate of
median survival (mp) of both groups was derived by the
formula used by Gillen and colleagues13 in a previous
systematic review:
mp =
(
k∑
i=1
wi
mi
)−1
wheremi denotes the median survival in a study population
i (with i ranging from 1 to k, where k is the number of
included studies) and wi refers to a study-specific weight
function. The number of study participants (divided by
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Fig. 1 PRISMA flow chart showing selection of articles for review
the total number of evaluable patients) was used as the
weight.
The overall resection rate and the R0 rate for both groups
were also calculated. The R0 rate was calculated for all
patients and also for those who actually underwent resec-
tion of the pancreatic cancer. For both the overall resection
rate and the R0 rate, the 95 per cent confidence interval
was calculated using a proportion calculator14. The signif-
icance of differences in proportions was assessed by means
of two-tailed Fisher’s exact test, with a significance level
α= 0⋅050, using SPSS® version 22.0.0.2 (IBM, Armonk,
New York, USA).
Results
A total of 18 828 records were identified, of which 122
screened were fully. Finally, 38 studies15–52 were included,
with 3484 patients (Fig. 1). Study characteristics are sum-
marized in Tables 1 and 2. Three RCTs, nine phase I or
II trials, 12 prospective cohort studies and 14 retrospec-
tive cohort studies were included. The range of median
age was 61⋅9–69⋅0 years in the upfront surgery group and
59–73 years in the neoadjuvant group (Tables 3 and 4).
Overall, neoadjuvant treatment was administered to 1723
of 1738 patients (99⋅1 per cent). All studies used at least
chemotherapy as neoadjuvant treatment, usually including
gemcitabine (26 of 35 studies). Radiotherapy was given as
part of the neoadjuvant treatment in 29 of 35 studies. No
study used radiotherapy as the sole neoadjuvant treatment.
The radiation dose ranged from 30 to 54 Gy.
Adjuvant therapy was initiated in ten of 12 upfront
surgery studies, and 68⋅6 per cent of patients who under-
went resection started adjuvant treatment. In the neoadju-
vant treatment group, adjuvant therapy was initiated in 18
of 35 studies, and 31 per cent of patients who had resection
of the pancreatic tumour started adjuvant therapy. Fewer
studies reported the numbers of patients who completed
adjuvant therapy (Tables 1 and 2).
Methodological quality
Results of the methodological quality assessment of
all studies are reported in Tables S1–S3 (supporting
information). Most studies were retrospective (14) or
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Table 1 Characteristics of 12 included studies that reported median overall survival after upfront surgery
Reference
No. of
patients Country Study design Tumour R0 criteria (mm)*
Adjuvant treatment
initiated (%)†
Adjuvant treatment
completed (%)
Casadei et al.15 20 Italy RCT R > 1 22 n.r.
Golcher et al.16 33 Germany RCT R n.s. 44 n.r.
Bao et al.17 78 USA Prospective R n.s. 78 n.r.
Raptis et al.18 102 UK Prospective R n.r. n.r. n.r.
Tzeng et al.19 52 USA Prospective R n.s. n.r. 60
Fujii et al.20 71 Japan Prospective BR > 1 100 42
Fujii et al.21 233 Japan Prospective R > 1 69 45⋅6
Barbier et al.22 85 France Retrospective R > 1 58 n.r.
Papalevoza et al.23 92 USA Retrospective R n.s. Adjuvant CRT: 66 n.r.
Kato et al.24 624 Japan Retrospective BR n.s. 78⋅7 n.r.
Adjuvant CT only: 69⋅9
Hirono et al.25 331 Japan Retrospective R+BR 0 BR-A: 84⋅5 76
Murakami et al.26 25 Japan Retrospective BR n.s. 48 n.r.
*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. †Among patients who underwent resection of
pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; prospective, prospective cohort study; BR, borderline resectable; retrospective,
retrospective cohort study; CRT, chemoradiotherapy; CT, chemotherapy; BR-A, borderline resectable with arterial involvement.
Table 2 Characteristics of the 35 included studies that report median overall survival after neoadjuvant treatment
Reference
No. of
patients Country Study design Tumour R0 criteria (mm)*
Neoadjuvant
treatment
Adjuvant
treatment
initiated (%)†
Adjuvant
treatment
completed (%)
Palmer et al.27 50 UK RCT R n.s. CT n.r. n.r.
Casadei et al.15 18 Italy RCT R > 1 CRT 75 n.r.
Golcher et al.16 33 Germany RCT R n.s. CRT 37 n.r.
Evans et al.28 86 USA Phase II R 0 CRT n.r. n.r.
Heinrich et al.29 28 Switzerland Phase II R n.s. CT n.r. n.r.
Le Scodan et al.30 41 France Phase II R n.s. CRT n.r. n.r.
Turrini et al.31 34 France Phase II R 0 CRT n.r. n.r.
Small et al.32 17 USA Phase II R+BR n.s. CRT n.r. n.r.
Esnaola et al.33 13 USA Phase II BR n.s. Mixed n.r. n.r.
Kim et al.34 62 USA Phase II R+BR n.s. CRT 63 92
O’Reilly et al.35 38 USA Phase II R n.s. CT 96 89
Shaib et al.36 13 USA Phase I BR n.s. CRT n.r. n.r.
Calvo et al.37 15 Spain Prospective R n.s. CRT n.r. n.r.
Ohigashi et al.38 38 Korea Prospective BR n.s. CRT 100 100
Katz et al.39 22 USA Prospective BR 0 CRT 67 90
Oh et al.40 38 Korea Prospective BR n.s. CRT 61 n.r.
Tzeng et al.41 141 USA Prospective BR n.s. CRT n.r. n.r.
Tzeng et al.19 115 USA Prospective R n.s. CRT 7⋅8 n.r.
Fujii et al.20 21 Japan Prospective BR > 1 CRT 100 56
Fujii et al.21 40 Japan Prospective R > 1 CRT 83 56
Ielpo et al.42 11 Spain Prospective BR n.s. CT 100 n.r.
Masui et al.43 18 Japan Prospective BR > 1 CT 93 n.r.
Takai et al.44 32 Japan Retrospective R n.s. CRT n.r. n.r.
Barbier et al.22 88 France Retrospective R > 1 CRT n.r. n.r.
Patel et al.45 18 USA Retrospective BR 0 CRT n.r. n.r.
Papalevoza et al.23 144 USA Retrospective R n.s. CRT 32⋅9 n.r.
Chuong et al.46 57 USA Retrospective BR 0 CRT 84 n.r.
Dholakia et al.47 50 USA Retrospective BR 0 CRT 42 n.r.
Boone et al.48 61 USA Retrospective R+BR n.s. Mixed n.r. n.r.
Rose et al.49 64 USA Retrospective BR > 1 CT/CRT 90 n.r.
Moningi et al.50 14 USA Retrospective BR n.s. CRT n.r. n.r.
Sho et al.51 99 Japan Retrospective R+BR n.s. CT/CRT n.r. R: 75
BR-V: 49
BR-A: 31
Rashid et al.52 121 USA Retrospective BR 0 CRT n.r. n.r.
Hirono et al.25 46 Japan Retrospective BR 0 Mixed 85 61
Murakami et al.26 52 Japan Retrospective BR n.s. CT 79 n.r.
*Definition of R0: > 1, more than 1 mm clearance from each margin; 0, no cancer cells along any margin. †Among patients who underwent resection of
pancreatic cancer. R, resectable; n.r., not reported; n.s., not specified; CT, chemotherapy; CRT, chemoradiotherapy; BR, borderline resectable;
prospective, prospective cohort study; retrospective, retrospective cohort study; BR-V, borderline resectable with venous involvement; BR-A, borderline
resectable with arterial involvement.
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Table 3 Median overall survival, resection rate and R0 rate after upfront surgery reported in 12 studies
Reference
No. of
patients
Median age
(years)
Median OS
(months)
Resection rate,
ITT (%) R0 rate* (%)
Patients with
positive lymph
nodes (%)*
Casadei et al.15 20 67⋅5 19⋅5 75 33 87
Golcher et al.16 33 65⋅1 14⋅4 70 70 57
Bao et al.17 78 68† 17⋅9 77 75 58
Raptis et al.18 102 64‡ 12 32⋅7 n.r. n.r.
Tzeng et al.19 52 61⋅9 25⋅3 92 81 81
Fujii et al.20 71 63 13⋅1 70 40 92
Fujii et al.21 233 67 23⋅5 87⋅6 70⋅1 71
Barbier et al.22 85 64 17 79 67 64
Papalezova et al.23 92 65† 13 74 79 62
Kato et al.24 624 63⋅8 12⋅6 86⋅4 65⋅9 57
Hirono et al.25 331 R: n.r. R: 20⋅9 R: 89⋅5 R: n.r. R: n.r.
BR-V: n.r. BR-V: 16⋅3 BR-V: 92 BR-V: n.r. BR-V: n.r.
BR-A: 69§ BR-A: 12⋅4 BR-A: 83⋅1 BR-A: 62⋅1 BR-A: 74⋅8
Murakami et al.26 25 67§ 11⋅6 92 17 78
Total 1746 Range 61⋅9–69 14⋅8 81⋅3 (79⋅4, 83⋅1) 66⋅9 (64⋅2, 69⋅6) 64⋅8 (62⋅0, 67⋅5)
Values in parentheses are 95 per cent confidence intervals. *Among patients who underwent resection of pancreatic cancer. †Mean age. ‡Including
patients with unresectable pancreatic tumours, who were not reported separately. §Including patients who received neoadjuvant treatment. OS, overall
survival; ITT, intention to treat; R, resectable; n.r., not reported; BR-V, borderline resectable with venous involvement; BR-A, borderline resectable with
arterial involvement.
prospective (12) cohort studies. The studies showed het-
erogeneity in treatment and potential bias in collecting
data. A common risk of bias was the heterogeneity of
neoadjuvant and adjuvant treatments within and between
the studies. Furthermore, there was wide variation in the
duration of follow-up; in eight studies the follow-up was
shorter than 12months. In addition, different criteria
were used for resectability, although most studies used the
NCCN guidelines.
Three RCTs were included, one27 of which randomized
between neoadjuvant gemcitabine or gemcitabine com-
bined with capecitabine in patients with resectable pancre-
atic cancer. The other two trials15,16 randomized between
neoadjuvant chemoradiotherapy and upfront surgery, but
both were terminated early owing to poor accrual.
Primary outcome
The weighted median overall survival by intention to treat
was 18⋅8months in the neoadjuvant group and 14⋅8months
in the upfront surgery group.
Upfront surgery
Twelve studies15–26 reported the median overall survival
of 1746 patients undergoing upfront surgery for resectable
or borderline resectable pancreatic cancer by intention
to treat (Figs 2 and 3). Overall, 81⋅3 per cent of 1746
patients underwent resection, with an overall weighted
median overall survival of 14⋅8 (range 11⋅6–25⋅3)months.
The weighted median overall survival of 819
patients with resectable pancreatic cancer was 17⋅7
(12–25⋅3)months15–19,21–23,25, compared with 12⋅8
(11⋅6–16⋅3)months for 927 patients with borderline
resectable pancreatic cancer20,24–26 (Figs 2 and 3). In the
largest (retrospective) study of Kato and colleagues24, 63
of 624 patients (10⋅1 per cent) with borderline resectable
pancreatic cancer also received neoadjuvant treatment
and the median overall survival of these patients was not
available separately. The outcome of the subgroup of
patients who actually underwent resection was reported in
seven16,18,22–26 of 12 studies; the weighted median overall
survival was 15⋅0months for these 1048 patients (not by
intention to treat).
Neoadjuvant treatment
Thirty-five studies15,16,19–23,25–52 reported median over-
all survival after neoadjuvant treatment of 1738 patients
with resectable or borderline resectable pancreatic can-
cer. The neoadjuvant regimens used are shown in Table 2.
The weighted median overall survival was 18⋅8 (range
9⋅4–50⋅2)months after neoadjuvant treatment.
For the 18 studies15,16,19,21–23,27–32,34,35,37,44,48,51 that
reported the median overall survival of 857 patients with
resectable pancreatic cancer, the weighted median overall
survival was 18⋅2 (10–50⋅2)months (Fig. 2). In the 21
studies20,25,26,32–34,36,38–43,45–52 reporting the median
overall survival after neoadjuvant treatment in 881 patients
with borderline resectable cancer, the weighted median
overall survival was 19⋅2 (11–32)months (Fig. 3).
The outcome for the subgroup of patients who
actually underwent resection was reported in 19
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Table 4 Median overall survival, resection rate and R0 rate after neoadjuvant treatment reported in 35 studies
Reference
No. of
patients
Median age
(years)
Median OS
(months)
Resection rate
ITT (%)
R0
rate (%)*
Patients with
positive lymph
nodes (%)*
Palmer et al.27 50 66 13⋅6 54 74 56
Casadei et al.15 18 71⋅5 22⋅4 61 64 55
Golcher et al.16 33 62⋅5 17⋅4 58 90 32
Evans et al.28 86 65⋅8 22⋅7 74 89 38
Heinrich et al.29 28 59 26⋅5 89 80 64
Le Scodan et al.30 41 59⋅3 9⋅4 63 81 50
Turrini et al.31 34 61⋅5† 15⋅5 50 100 24
Small et al.32 17 62‡ R: 10⋅2 R: 43 n.r. 0
BR: 11⋅2 BR: 30
Esnaola et al.33 13 60 24⋅1 69 92 n.r.
Kim et al.34 62 64‡ R: 26⋅5 R: 57 85 44
BR: 18⋅4 BR: 72
O’Reilly et al.35 38 73 27⋅2 71 74 67
Shaib et al.36 13 64 11 62 n.r. 13
Calvo et al.37 15 61 10 60 78 n.r.
Ohigashi et al.38 38 66 32 82 97 10
Katz et al.39 22 64 21⋅7 68 93 33
Oh et al.40 38 59 21⋅2 61 78 4
Tzeng et al.41 141 63 19⋅1 59⋅6 91⋅7 48⋅8
Tzeng et al.19 115 65⋅5 28 82⋅6 89⋅5 51⋅5
Fujii et al.20 21 66 29⋅1 86 100 17
Fujii et al.21 40 65 24⋅9 90 86 39
Ielpo et al.42 11 61⋅8† 20 73 100 n.r.
Masui et al.43 18 63 21⋅7 83 87 33
Takai et al.44 32 61⋅8 19⋅2 75 n.r. n.r.
Barbier et al.22 88 65 15 43 92 29
Patel et al.45 18 67 15⋅6 50 89 n.r.
Papalezova et al.23 144 64 15 53⋅0 78⋅0 25
Chuong et al.46 57 64‡ 16⋅4 56 97 34
Dholakia et al.47 50 63⋅5 17⋅2 58 93 28
Boone et al.48 61 64‡ R: 20 R: 95 R: 86 n.r.
BR: 22 BR: 83 BR: 70
Rose et al.49 64 66 23⋅6 48 87 58
Moningi et al.50 14 67⋅2‡ 14⋅4 29 100 n.r.
Sho et al.51 99 R: 66⋅4† R: 50⋅2 R: 100 R: 98 n.r.
BR-V: 66⋅3† BR-V: 26⋅6 BR-V: 97 BR-V: 97
BR-A: 66⋅0† BR-A: 18 BR-A: 84 BR-A: 81
Rashid et al.52 121 67 17 45⋅5 98⋅4 63⋅6
Hirono et al.25 46 69§ 18 87 80 78
Murakami et al.26 52 67§ 27⋅1 90 72 72
Total 1738 Range 59–73 18⋅8months 66⋅0 (63⋅7, 68⋅2) 86⋅8 (84⋅6, 88⋅7) 43⋅8 (40⋅6, 47⋅1)
Values in parentheses are 95 per cent confidence intervals. *Among patients who underwent resection of pancreatic cancer. †Mean age. ‡Including
patients with unresectable pancreatic tumours, who were not reported separately. §Including patients who received upfront surgery. OS, overall survival;
ITT, intention to treat; R, resectable; n.r., not reported; BR, borderline resectable; BR-V, borderline resectable with venous involvement; BR-A,
borderline resectable with arterial involvement.
studies16,19,22,23,25–31,34,37,40,41,44,46,47,52, and the weighted
median overall survival was 26⋅1months for these 764
patients (not by intention to treat).
Neoadjuvant chemotherapy versus chemoradiotherapy
Of all studies including patients who received neoad-
juvant treatment, six used chemotherapy alone, 24
used chemoradiotherapy, and five used neoadjuvant
chemotherapy in some patients and chemoradiotherapy
in others. The weighted median overall survival
was 20⋅9 (range 13⋅6–27⋅2)months for patients who
received chemotherapy alone26,27,29,35,42,43 and 17⋅8
(9⋅4–32)months15,16,19–23,28,30–32,34,36–41,44–47,50,52 for
chemoradiotherapy alone. Because of the heterogeneity
between radiation dose and chemotherapy schedules,
subset analyses should be interpreted with caution.
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Upfront surgery
Bao et al.17
Raptis et al.18
Barbier et al.22
Papalezova et al.23
Tzeng et al.19
Casadei et al.15
Golcher et al.16
Fujii et al.21
Hirono et al.25
Calvo et al.37
Palmer et al.27
Evans et al.28
Heinrich et al.29
Takai et al.44
Le Scodan et al.30
Turrini et al.31
Barbier et al.22
Small et al.32
Papalezova et al.23
Kim et al.34
Boone et al.48
O’Reilly et al.35
Tzeng et al.41
Casadei et al.15
Golcher et al.16
Sho et al.51
Fujii et al.21
Neoadjuvant treatment
RCT
0 10 20 30 40 50
Survival (months)
Prospective cohort study
Retrospective study
Phase I or II study
Fig. 2 Median overall survival, with 95 per cent confidence intervals, for patients with resectable pancreatic cancer after upfront surgery
and after neoadjuvant treatment. The square of radius of the spheres is related to number of patients in the study
Secondary outcomes
Resection rate and R0 rate
The overall resection rate was lower in patients who had
neoadjuvant treatment than in those who had upfront
surgery (66⋅0 versus 81⋅3 per cent; P< 0⋅001).
After upfront surgery, the resection rate in all 1746
patients was 81⋅3 (95 per cent c.i. 79⋅4 to 81⋅3) (range
32⋅7–92) per cent. For patients with resectable pancreatic
cancer, the resection rate was 76⋅8 (95 per cent c.i. 73⋅8 to
79⋅7) per cent, compared with 85⋅3 (82⋅9 to 87⋅5) per
cent for those with borderline resectable pancreatic cancer
(P< 0⋅001).
For patients who received neoadjuvant treatment, the
resection rate was reported in 35 studies15,16,20–23,25–52
and was 66⋅0 (95 per cent c.i. 63⋅7 to 68⋅2) (range 29–100)
per cent. For patients with resectable pancreatic cancer, the
resection rate was 67⋅0 (95 per cent c.i. 63⋅7 to 70⋅1) per
cent, compared with 65⋅0 (61⋅8 to 68⋅2) per cent for those
with borderline resectable pancreatic cancer (P= 0⋅418).
The resection rate for patients in the neoadjuvant group
who underwent an exploratory laparotomy was 91⋅2 per
cent.
The R0 resection rate (only for patients who underwent
resection) was higher in patients who had neoadjuvant
treatment (86⋅8 versus 66⋅9 per cent; P< 0⋅001). The R0
resection rate was also higher with neoadjuvant treatment
when the results were reported by intention to treat (58⋅0
versus 54⋅9 per cent; P= 0⋅088). This difference is obvi-
ously smaller, because it is the resection rate multiplied by
the R0 rate.
The R0 resection rate was reported in 11
studies15–17,19–26 after upfront surgery and was 66⋅9
(95 per cent c.i. 64⋅2 to 69⋅6) (range 17–81) per cent. After
upfront surgery, the R0 resection rate was 71⋅4 per cent
for patients with resectable pancreatic cancer, and 63⋅9
per cent for those with borderline resectable pancreatic
cancer. For patients treated with neoadjuvant therapy who
underwent exploratory laparotomy followed by resection,
the R0 resection rate was 86⋅8 (95 per cent c.i. 84⋅6 to 88⋅7)
(range 38⋅9–100) per cent. After neoadjuvant treatment,
the R0 resection rate was 85⋅0 per cent among patients
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Fig. 3 Median overall survival, with 95 per cent confidence intervals, for patients with borderline resectable pancreatic cancer after
upfront surgery and after neoadjuvant treatment. The square of radius of the spheres is related to number of patients in the study.
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with resectable pancreatic cancer and 88⋅6 per cent for
those with borderline resectable cancer.
Pathological lymph node rate
The pathological lymph node rate was reported in 11
studies15–17,19–26 after upfront surgery and was 64⋅8 (95
per cent c.i. 62⋅0 to 67⋅5) per cent, compared with 43⋅8
(40⋅6 to 47⋅1) per cent after neoadjuvant treatment in
27 studies15,16,19–23,25–32,34–36,38–41,43,46,47,49,52. This dif-
ference in pathological lymph node rates between the two
groups was significant (P< 0⋅001).
Reasons for not performing surgery
Of the 35 neoadjuvant therapy studies, 29 reported the
reason for not performing exploratory surgery. In total,
306 patients (17⋅8 per cent) did not proceed to exploratory
surgery. Progression of disease (locally advanced or metas-
tasis) was the most common reason for not undertaking
exploratory surgery in 64⋅4 per cent of these patients. In
total, 55 patients (18⋅0 per cent) could not undergo surgery
because of severe side-effects or deterioration of perfor-
mance after neoadjuvant treatment, representing 3⋅2 per
cent of all patients starting neoadjuvant treatment. For the
remaining patients there were other reasons, or the reason
was not known. The reasons for not performing tumour
resection during exploratory surgery were reported in 23
of the 35 studies (Table S4, supporting information). Resec-
tion was not undertaken in at least 532 patients (15⋅3 per
cent of all 3484 included patients). The most common rea-
son for this was distant metastasis in 42⋅5 per cent of these
patients. Disease progression was the reason for not resect-
ing the tumour in 25⋅6 per cent.
Toxicity
There was a wide range of reported toxicity of neoad-
juvant treatment across studies. The most common
reported adverse events were gastrointestinal (emesis,
nausea and diarrhoea) and haematological (thrombopenia,
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leucopenia). Toxicity of at least grade III was reported in
21 studies15,16,20,25,27–34,36–39,42–44,46,50, with a rate of up
to 64 per cent, involving mostly leucopenia, thrombocyto-
penia, nausea and fatigue. Katz and colleagues39 reported
a grade III toxicity rate of 64 per cent, in a study in which
FOLFIRINOX (leucovorin, 5-fluorouracil, irinotecan and
oxaliplatin) chemotherapy was combined with radiother-
apy at a dose of 50⋅4 Gy. Grade IV toxicity was reported in
13 studies, and consisted mostly of haematological adverse
events.
Discussion
In this systematic review, median overall survival
was 18⋅8months after neoadjuvant treatment versus
14⋅8months after upfront surgery of resectable or border-
line pancreatic cancer in intention-to-treat analysis. The
R0 resection rate and pathological lymph node rate were
also improved in the neoadjuvant group. These results sug-
gest the superiority of neoadjuvant treatment over upfront
surgery. Previous studies13,53 reported outcomes of patients
who actually underwent resection, rather than reporting
by intention to treat, thus introducing a survival bias.
Median survival times for patients who actually under-
went resection were 26⋅1months in the neoadjuvant group
and 15⋅0months for upfront surgery in this review. This
difference in median overall survival between the groups
(11⋅1months) is much bigger than the difference in the
intention-to-treat analysis (4⋅0months). Reporting by
intention to treat reduces potential bias in treatment effect
as not all patients proceed to surgery, and a large pro-
portion of patients do not receive adjuvant chemotherapy
owing to postoperative complications. Prospective phase
II studies investigating the role of neoadjuvant treatment
have to report on all patients included in the trial by inten-
tion to treat54. Therefore, for a fair comparison, upfront
surgery studies and observational studies of neoadjuvant
treatment should also report by intention to treat.
In the present review, 17⋅8 per cent of patients who
had neoadjuvant treatment did not undergo exploratory
surgery. This selects out patients with an aggressive pan-
creatic cancer that would probably have progressed in a
short time after surgery anyway, thus avoiding a poten-
tially harmful operation. In the upfront surgery group,
the resection rate for patients with borderline resectable
pancreatic cancer was significantly higher than that for
patients with resectable tumours (85⋅3 versus 76⋅8 per cent
respectively). This is a counterintuitive finding, as one
would expect the resection rate to be higher for resectable
pancreatic cancer. There is no good explanation for this
finding, but the different criteria being used worldwide for
assessing resectability or suboptimal preoperative assess-
ment on CT may play a role. Centralization of pancreatic
surgery has led to increased resection rates55, but this was
not investigated here.
The R0 resection rate among patients actually under-
going tumour resection was significantly better in the
neoadjuvant treatment group, which is in line with the
hypothesis that neoadjuvant treatment provides higher R0
rates than surgery alone56. The R0 resection rate after
upfront surgery is comparable to rates of 29–81 per cent,
depending on the R0 criteria being used, in recent large
series of pancreatic cancer resection1,57,58. The pathologi-
cal lymph node rate was also significantly different between
the upfront surgery and neoadjuvant treatment groups,
which may be the result of the neoadjuvant treatment caus-
ing regression of lymph node metastases59.
No difference in surgical morbidity and mortality has
been reported in studies comparing neoadjuvant treat-
ment with upfront surgery60–62. A possible advantage of
neoadjuvant radiation is the development of pancreatic
fibrosis, which may be associated with reduced occur-
rence of pancreas fistula after resection60,61,63. Adjuvant
chemotherapy is the current standard of care after resec-
tion of pancreatic cancer1, but this treatment is often not
given, or not completed, owing to a prolonged complicated
postoperative course, or the preference of the patient or
doctor. Data from the Netherlands Cancer Registry64
revealed that only 54 per cent of all patients undergoing
pancreatoduodenectomy received adjuvant chemotherapy,
because of toxicity, age and other factors. In the present
review, the toxicity reported most frequently consisted of
adverse gastrointestinal and haematological events. Over-
all, treatment-related toxicity was given as the reason for
not proceeding to exploratory surgery in only 3⋅2 per cent
of the 1723 patients who started neoadjuvant treatment.
Median overall survival varied widely across the studies,
which may be explained by the different criteria used
for resectability. Most studies used the NCCN or MD
Anderson Cancer Center criteria for resectability65,66, but
some studies used neither of these. Objective definitions of
resectability are critical for the conduct of clinical trials of
neoadjuvant treatment. Another explanation for the het-
erogeneity may be the variation in neoadjuvant treatment
regimens across studies. The difference in receipt of post-
operative adjuvant treatment (68⋅6 per cent in the upfront
surgery group versus 31 per cent in the neoadjuvant group)
may in part be explained by the fact that these patients had
already received part or all of their systemic therapy before
surgery.
The expert consensus statement of the AHPBA67
indicates that neoadjuvant therapy provides a rational
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alternative to an upfront surgery approach and could
be considered in all patients with resectable pancreatic
cancer. Evidence from RCTs is still lacking. The Dutch
Pancreatic Cancer Group has just finished accrual of the
multicentre randomized PREOPANC trial (EU Clinical
Trials Register: 2012-003181-40) of neoadjuvant chemo-
radiotherapy versus upfront surgery68. The hypothesis
is that neoadjuvant chemoradiotherapy may result in
an increase in R0 resection rate and overall survival in
patients with resectable or borderline resectable pan-
creatic cancer68. The trial has randomized the required
248 patients during a 4-year interval and the first results
are expected in 2018. Five other randomized trials69–73
are ongoing in Germany, Switzerland and Norway to
investigate the role of neoadjuvant treatment in resectable
pancreatic cancer. Two previous RCTs15,16 from Italy and
Germany were terminated early because of poor accrual.
Some limitations of the present systematic review must
be taken into account. First, the quality of the included
studies is moderate; the majority are retrospective studies,
with high suspicion of bias. Only three studies were RCTs,
and only two of these, with a total of 104 patients, random-
ized between upfront surgery and neoadjuvant treatment
followed by surgery. Both these studies were terminated
early. Owing to the clinical and methodological hetero-
geneity, no network analysis could be performed. Despite
the limitations, the results provide the most reliable sur-
vival data, reported by intention to treat, in patients with
resectable or borderline resectable pancreatic cancer.
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Editor’s comments
Pancreas cancer is a systemic disease, so improved control must come from a systemic approach to management.
At the time of writing, several centres have already adopted liberal use of neoadjuvant chemotherapy in patients
with resectable pancreatic cancer. In contrast, national guidelines in the UK and elsewhere discourage neoadjuvant
chemotherapy outside clinical trials. In the current meta-analysis, and in a recent phase II trial1 the toxicity was
tolerable, but standard chemotherapy regimens have changed, which may alter safety and efficacy. Nonetheless, with
such poor long-term outcome in pancreas cancer, present research does suggest that neoadjuvant chemotherapy is
associated with better outcomes. Whether this simply reflects better selection of biological winners, or a genuinely
improved disease control remains to be demonstrated in ongoing randomized clinical trials.
Kjetil Søreide
Editor, BJS
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